Results 201 to 210 of about 36,987 (240)
Some of the next articles are maybe not open access.

Immunotherapies in CLL

2013
Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy.
Jae H, Park, Renier J, Brentjens
openaire   +2 more sources

Maintenance in CLL

Blood, 2013
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).
openaire   +2 more sources

Richter transformation of CLL

Expert Review of Hematology, 2016
Richter transformation (RT) represents an aggressive transformation of chronic lymphocytic leukemia (CLL), most commonly into diffuse large B cell lymphoma (DLBCL). It occurs in around 5% of patients with CLL.This review will focus on the biology and treatment of RT. We also address the management of RT in the era of targeted therapies. Based on clonal
Nitin, Jain, Michael J, Keating
openaire   +2 more sources

Looking for CLL genes

Leukemia & Lymphoma, 2008
We learn from the article of Sellick et al. [1] that germ line mutations in the RAD (51, 51AP1, 51B, C, D, 52 and 54L) sequences are most probably not related to the genetics of CLL.
Viggo, Jønsson   +3 more
openaire   +2 more sources

Apoptosis Deregulation in CLL

2013
The description of apoptosis and the identification of the genes that regulate it have proved pivotal to our understanding of how cancer cells accumulate and ultimately cause morbidity and mortality. It has become increasingly clear that in CLL the balance between the pro- and anti-apoptotic members of the BCL2 family of apoptotic regulatory proteins ...
Chris, Fegan, Chris, Pepper
openaire   +2 more sources

Molecular Profiling in CLL

Hematology, 2008
Abstract Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous clinical course, with some patients requiring immediate therapy and others living without need for treatment for decades. There has been considerable interest in the underlying molecular mechanisms of this heterogeneity to understand not only the expected clinical
openaire   +2 more sources

CLL Biology and Prognosis

Hematology, 2005
AbstractChronic lymphocytic leukemia (CLL) follows an extremely variable course with survival ranging from months to decades. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in CLL patients.
openaire   +2 more sources

Angiopoietin-2 in CLL

Blood, 2010
Elevated plasma levels of the angiogenic factor Ang-2 correlated with poor prognosis in a larger series of CLL patients. Ang-2 levels may reflect crosstalk between CLL cells and their microenvironment, specifically related to angiogenesis and endothelial cells, and therefore emphasize the importance of angiogenesis in CLL. .
openaire   +2 more sources

Home - About - Disclaimer - Privacy